Eagle Genomics, a Cambridge, UK – based pioneer in applying network science to biology – particularly linked to the microbiome, closed $9m a scale-up funding round.
Backers included Environmental Technologies Fund (ETF) and a consortium of investors led by Granpool Innovative Investments, and including bpd partners, Anatom Holding and Albert-László Barabási, among others.
The company intends to use the funds to further develop the capabilities of its platform and to drive further commercial expansion across Europe and the US.
Led by Anthony Finbow, CEO, Eagle Genomics is a pioneer in applying network science to biology – particularly linked to the microbiome. Its AI-augmented knowledge discovery platform, e[datascientist]™, helps companies looking to innovate with next-generation food, personal care, cosmetics and agritech products, supported by science. The platform harnesses the latest graph technology, and Microsoft’s advanced machine learning and cognitive services.
Eagle Genomics became Microsoft Genomics’ first microbiome partner in 2018. Today, the global business has operations in the world’s major centres for genomics and AI. These include Cambridge’s Wellcome Genome Campus and London’s Knowledge Quarter in the UK; Microsoft’s AI Factory in Paris; Potsdam Science Park in Berlin; JLABS in New York, and HITEC City in Hyderabad, India.